A phase IIb/III trial of MLN 591RL [177Lu-J591] in patients with castrate-resistant prostate cancer.

Trial Profile

A phase IIb/III trial of MLN 591RL [177Lu-J591] in patients with castrate-resistant prostate cancer.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors ATLAB Pharma; BZL Biologics; Telix Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top